Posted by Michael Wonder on 05 Mar 2024
Nine drug formularies in Canada list Evenity for reimbursement for the treatment of osteoporosis in post-menopausal women as high risk of fracture
5 March 2024 - Multiple formulary listings are a step forward to ensuring that post-menopausal women have access to medicines that address the unmet medical needs associated with osteoporosis.
Amgen Canada announced today that Evenity (romosozumab) has been listed for reimbursement on nine of Canada's public formularies. With this announcement most post-menopausal women in Canada will be able to access this biologic treatment.
